{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
  "id": "02975668",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
  "summary": "### Summary of ASX Announcement: **AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Presentation**  \n\n#### **Material Information for Capital Markets/Trading Decisions:**  \n- **FY25 Financial Highlights**  \n  - **Revenue**: NZD $208.0M (6% YoY growth; 5-year CAGR: 14%).  \n  - **Operating Profit**: NZD $17.6M (vs. NZD $24.2M in FY24), impacted by lower licensing income (NZD $0.7M vs. NZD $8.5M in FY24) and strategic investments.  \n  - **Dividend**: 1.8 NZ cents per share (up from 1.6 NZ cps in FY24).  \n  - **Net Debt**: NZD $14.5M (down from NZD $16.2M in FY24); debt-to-equity ratio declining.  \n  - **Cash Flow**: R&D spend increased to NZD $15.0M (FY24: NZD $12.4M).  \n\n- **Operational Highlights**  \n  - **ANZ Growth**: Australia sales up 17% (NZD $53.8M); New Zealand sales NZD $127.1M.  \n  - **International**: Sales in ~80 countries; product/royalty income NZD $15.4M (down from NZD $19.3M due to destocking).  \n  - **Product Pipeline**: 8 patented products in development; 24+ off-patent injectables progressing.  \n  - **Expansion**: Launches in UK, EU, USA, Canada, South Africa, and Asia (Hong Kong/Singapore).  \n\n- **Outlook**  \n  - **FY26 Guidance**: Operating profit expected between NZD $20M\u201324M.  \n  - **FY27 Target**: Revenue goal of NZD $300M.  \n\n#### **Other Material Points**  \n- **Governance**: Allison Yorston appointed as Independent Director; ESG targets met.  \n- **R&D**: Focus on commercialization of Maxigesic variants (IV, pediatric, oral) and novel therapies (e.g., Pascomer for Prader-Willi syndrome, Iron IV).  \n\n#### **Omitted**: Board nominations (Resolution 2\u20133), auditor remuneration, historical/organizational details.  \n\n**Format Note**: Structured for brevity; excluded operational minutiae and non-material resolutions.",
  "usage": {
    "prompt_tokens": 5861,
    "completion_tokens": 511,
    "total_tokens": 6372,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:33:22.491195"
}